Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Inaxaplin · VX-147, IXP

Small molecule · developed by VERTEX PHARMACEUTICALS INC / MA

Phase 2/3 Most advanced trial

VRTX Developer

2 Registered trials

What is Inaxaplin?

Inaxaplin is an investigational small-molecule drug studied in Proteinuric Kidney Disease.

At a glance

Also known as: VX-147, IXP
Drug type: Small molecule
Therapy area: Renal & urology
Developer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: S2SJ2RVZ6Y

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05312879	Phase 2/3	Proteinuric Kidney Disease	Recruiting	VRTX
NCT06794996	Phase 2	Proteinuric Kidney Disease	Completed	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Proteinuric Kidney Disease

More from VERTEX PHARMACEUTICALS INC / MA

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2 VX-272 Phase 1

Sources

ClinicalTrials.gov NCT05312879

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind Inaxaplin

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z